Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.
Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.
